FDA looks into reassessing criteria around rare disease trials, endpoint selection
As more rare disease treatments make their way to the FDA, the agency on Monday called for further outside input as it grapples with how much efficacy and safety data are sufficient to inform an ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.